Life

Scientists identify protein that allows coronavirus to ‘hide’ from immune system

Scientists have identified an enzyme that allows Sars-Cov-2 – the virus that causes Covid-19 – to stay under the human immune system's radar
Scientists have identified an enzyme that allows Sars-Cov-2 – the virus that causes Covid-19 – to stay under the human immune system's radar Scientists have identified an enzyme that allows Sars-Cov-2 – the virus that causes Covid-19 – to stay under the human immune system's radar

SCIENTISTS have identified a protein in coronavirus that acts as a “Trojan horse” by hiding it from the human body’s natural immune system.

Called NSP16, the enzyme allows Sars-Cov-2 – the virus that causes Covid-19 – to stay under the radar by chemically modifying its RNA, or genetic material.

According to the team led by Oxford Brookes University, this Trojan horse feature allows the virus to replicate in human cells and spread throughout the body.

The researchers said they have also identified a series of small molecules which are able to inhibit the function of NSP16, which could lead to the development of new drugs to treat Covid-19.

Dr Victor Bolanos-Garcia, senior lecturer in clinical biochemistry at Oxford Brookes University, said: “Although several vaccine programmes are currently under way, including the recently announced Pfizer-BioNTech where preliminary data suggest a 90 per cent efficacy, and some drugs have been repurposed to aid the treatment of Covid-19, effective drug therapies to treat the virus do not currently exist.

Read More: Scientists identify protein that makes coronavirus highly infectious

“Many viral diseases are treated with antiviral drugs. Therefore, expanding the repertoire of therapeutic drugs to treat Covid-19 is important and timely.”

Dr Bolanos-Garcia, who is lead author on the paper published in the journal Catalysts, added: “Stopping the NSP16 enzyme from functioning leaves the virus RNA exposed to recognition by the human immune system, which severely limits the replication of the Sars-Cov-2 virus in infected cells.

“The small molecules we have identified as inhibitors of NSP16 show promising pharmacological properties.

“They provide a solid scientific base to develop novel inhibitors of NSP16 to treat Covid-19.”